MétaCan
Menu
Back to cohort
Record W2916433178 · doi:10.1093/jac/dkr097

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

2011· article· en· W2916433178 on OpenAlexaff
Donald E. Low, Thomas M. File, Paul B. Eckburg, George H. Talbot, H. David Friedland, Jon Lee, Lily Llorens, Ian A. Critchley, Dirk Thye, Jorge Corral, Eduardo Giugno, Maria del Rosario Gonzalez Arzac, Diego Marcelo Maurizi, Javier Altclas, Germán Ambasch, Abel Jasovich, Angel Ramon Minguez, María Eugenia Oliva, Osvaldo Teglia, Carlos Bergallo, María Mastruzzo, Graciana Morera, Pabio Gustavo Scapellato, Ricardo Lamberghini, Analía Mykietiuk, Christian Remolif, Manuel Jose Barros Monge, Maria Isabel Enriqueta Campos Barker, Sara Mireya Chernilo Steinmann, Pablo Antonio Gaete Gutierrez, Sylvia Susana Muñoz Vejar, Mario Andres Calvo Arellano, Carolina Eugenia Chahin Anania, Arturo Jáuregui Cruz, Gerardo Amaya Tapia, Moises Acuna Kaldman, Eduardo Rodríguez-Noriega, E Prado, Carlos A. Ramos, Irina V. Andreeva, Р. А. Абышев, Yuri Antonovsky, Marina Balyuzek, Alla L. Esina, Alexander Gorelov, О.А. Хрусталев, Roman S. Kozlov, Vladislav Novozhenok, Veronika B. Popova, Svetlana Sobchenko, В. И. Трофимов, S B Yakovlev, К. П. Жидков, Luminta Gabriela Ambert, Carmen Georgeta Fierbinteau, Valentina Ionescu, Mihai Marius Muresan, Cristina Tănăseanu, Ognian Georgiev, Valdimir Hodzhev, Rosen Marinov, Hristo Metev, M Peneva, Dimitar Popov, Milkana Simeonova, Ivars Krastiņš, Viktors Lovcinovsk, Viesturs Šiliņš, Vita Svarcberga, Joachim Bargon, T. Bauer, Rolf Bergmann, F. Meyer, Thomas Mueller, Tobias Welte, Sven Glaeser, Peter Hammerl, Hartmut Kern, Stefan Krueger, P. Kujath, Achim Lies, Tom Schaberg, Oliver Schmalz, Wolfgang Schütte, Ryszarda Chazan, Dorota Górecka, Barbara Rogala, Adam Antczak, Tomasz Grodzicki, Karina Jahnz—Rö, Janusz Milanowski, P Nalepa, Malgorzata Wróbel-Rajzer, Hanna Szelerska-Twardosz, I Grzelewska-Rzymowska, Tomasz Kachel, Andrzej Marciniak, Bernard Panaszek, Andrzej Szczeklik, Jerzy Kozielski, Rafał Harat, Dariusz Jastrzebsk, Jacek Juszczak, Violetta Labij, N Vetter, J Bolitschek, Josef Eckmayr, Sándor Molnár, Zsolt Pápai-Székely, János Szegedi, Ilona Vinkler, Mykhaylo Borscchivskyy, Oleksandr Dziublyk, G. V. Dzyak, Oleg Kraydaschenko, Yuriy Mostovoy, Iurii Rudyk, V. Sushko, Вадим Анатолійович Візір, Amal Bhattacharya, Mahabala Chakrapan, George D′Souza, G.S. Malpani, Parthiv Mehta, KL Narasimha Rao, Deepak Talwar

Bibliographic record

VenueJournal of Antimicrobial Chemotherapy · 2011
Typearticle
Languageen
FieldMedicine
TopicPneumonia and Respiratory Infections
Canadian institutionsUniversity Health NetworkMount Sinai Hospital
Fundersnot available
KeywordsCeftriaxoneMedicineCephalosporinRandomized controlled trialPneumoniaAntibacterial agentInternal medicineAntibioticsMicrobiologyBiology

Abstract

fetched live from OpenAlex

OBJECTIVES: Ceftaroline (active form of the prodrug ceftaroline fosamil) is a novel cephalosporin with activity against pathogens commonly associated with community-acquired pneumonia (CAP), including Streptococcus pneumoniae and Gram-negative pathogens. This randomized, double-blind, Phase III study evaluated the efficacy and safety of ceftaroline fosamil in treating patients with CAP. The primary objective was to determine non-inferiority [lower limit of 95% confidence interval (CI) ≥ -10%] of clinical cure rates achieved with ceftaroline fosamil compared with those achieved with ceftriaxone in the clinically evaluable (CE) and modified intent-to-treat efficacy (MITTE) populations. METHODS: Patients hospitalized in a non-intensive care unit setting with CAP of Pneumonia Outcomes Research Team (PORT) risk class III or IV requiring intravenous (iv) therapy were randomized (1:1) to receive 600 mg of ceftaroline fosamil iv every 12 h or 1 g of ceftriaxone iv every 24 h. Clinical cure, microbiological response, adverse events (AEs) and laboratory tests were assessed. FOCUS 2 registration number NCT00509106 (http://clinicaltrials.gov/ct2/show/NCT00509106). RESULTS: The study enrolled 627 patients, 315 of whom received ceftaroline fosamil and 307 of whom received ceftriaxone. Patients in both treatment groups had comparable baseline characteristics. Clinical cure rates were as follows: CE population, 82.1% (193/235) for ceftaroline fosamil and 77.2% (166/215) for ceftriaxone [difference (95% CI), 4.9% (-2.5, 12.5)]; and MITTE population, 81.3% (235/289) for ceftaroline fosamil and 75.5% (206/273) for ceftriaxone [difference (95% CI), 5.9% (-1.0, 12.7)]. Clinical cure rates for CAP caused by S. pneumoniae in the microbiological MITTE (mMITTE) population were 83.3% (35/42) and 70.0% (28/40) for ceftaroline fosamil and ceftriaxone, respectively. Ceftaroline fosamil and ceftriaxone were well tolerated, with similar rates of AEs, serious AEs, deaths and discontinuations due to an AE. The most common AEs for ceftaroline fosamil-treated patients were diarrhoea, headache, hypokalaemia, insomnia and phlebitis, and the most common AEs for ceftriaxone-treated patients were diarrhoea, insomnia, phlebitis and hypertension. CONCLUSIONS: Ceftaroline fosamil achieved high clinical cure and microbiological response rates in patients hospitalized with CAP of PORT risk class III or IV. Ceftaroline fosamil was well tolerated, with a safety profile that is similar to that of ceftriaxone and other cephalosporins. Ceftaroline fosamil is a promising agent for the treatment of CAP.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.012
Threshold uncertainty score0.041

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.003
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0010.000
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.0120.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.048
GPT teacher head0.318
Teacher spread0.270 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations185
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Antimicrobial ChemotherapySame topicPneumonia and Respiratory InfectionsFrench-language works237,207